Many preclinical studies showed high efficacy of CCL2/CCR2 antagonists; for instance, targeting CCR2 with a small-molecule inhibitor not only reduced recruitment of M2-type macrophages but also induced tumor infiltration of activated CD8+ T cells (87). Here, CCL2 is linked to neoplasm.